Markt oder Branche auswählen:
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| NEUROCRINE BIOSCIENCES | 25 | 17 | -0,26 % | ||
| AMGEN | 10 | 27 | -0,07 % | ||
| BIONTECH | 5 | 13 | +0,13 % | ||
| BIOGEN | 4 | 54 | -0,20 % | ||
| IMMUNITYBIO | 4 | 3 | -0,73 % | ||
| IDEAYA BIOSCIENCES | 3 | 3 | -1,41 % | ||
| BIOCRYST PHARMACEUTICALS | 3 | - | +1,43 % | ||
| DENALI THERAPEUTICS | 3 | - | -2,18 % | ||
| QUANTUM-SI | 3 | - | 0,00 % | ||
| SUMMIT THERAPEUTICS | 2 | 12 | -3,51 % |
- 24 h
- 7 Tage
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 03:26 | Mesoblast's Ryoncil Achieves US$30.3 Million in Net Sales for March Quarter | 2 | Finance News Network | ||
| 03:06 | Mesoblast Limited: Ryoncil Continues Successful First Year Launch with Net Sales of US$30.3M in March Quarter | 1 | GlobeNewswire (USA) | ||
| 03:05 | Mesoblast shares: Ryoncil underpins strong earnings growth | 1 | The Motley Fool Australia | ||
| 02:27 | Why Biogen Stock Got Mashed on Monday | 2 | The Motley Fool | ||
| 02:27 | Why ImmunityBio Stock Slumped on Monday | 1 | The Motley Fool | ||
| 01:12 | MESOBLAST LIMITED: Ryoncil Net Revenue for the Quarter Increases to US$30.3M | 1 | ASX | ||
| 00:26 | Precigen, Inc. (PGEN) Poised for Growth on Respiratory Papillomatosis Treatment Prospects | 1 | Insider Monkey | ||
| 00:26 | CytomX Therapeutics (CTMX) Making Progress on Key Metastatic Colorectal Cancer Treatment | 1 | Insider Monkey | ||
| 00:26 | Taysha Gene Therapies (TSHA) Making Progress on Crucial Rett Syndrome Treatment | 1 | Insider Monkey | ||
| 00:26 | Recursion Pharmaceuticals Inc. (RXRX) Partners with Citeline to Develop AI-Powered ClinTech Platform | 2 | Insider Monkey | ||
| 00:02 | Moderna, Inc.: Moderna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026 | 413 | ACCESS Newswire | CAMBRIDGE, MA / ACCESS Newswire / April 6, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present late-breaking oral presentations on revaccination data for both mRNA-1010... ► Artikel lesen | |
| Mo | Neurocrine's $2.9B Soleno Buyout Brings What Could Become It's Next Blockbuster Drug | 1 | MedCity News | ||
| Mo | Clear Street raises Protagonist Therapeutics price target on drug potential | 1 | Investing.com | ||
| Mo | Tapestry beruft Pinterest-CTO Matt Madrigal in den Verwaltungsrat | 3 | Investing.com Deutsch | ||
| Mo | Wedbush raises Neurocrine Bio stock price target on acquisition | 1 | Investing.com | ||
| Mo | Tapestry appoints Pinterest CTO Matt Madrigal to board | 2 | Investing.com | ||
| Mo | Ascendis Pharma's YUVIWEL gains orphan drug exclusivity in U.S. | 1 | Investing.com | ||
| Mo | ImmunityBio responds to FDA scrutiny over Anktiva promotional claims with new protocols | 7 | FiercePharma | ||
| Mo | Ascendis Pharma: Ascendis Receives Orphan Drug Exclusivity and Launches YUVIWEL (Navepegritide) in the United States | 2 | GlobeNewswire (USA) | ||
| Mo | Amgen-Studienergebnisse zu Tepezza belasten Viridian-Aktie | 6 | Investing.com Deutsch |
1 2 3 4 5 Weiter >>
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.